FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP) TREATMENT MARKET ANALYSIS

Fibrodysplasia Ossificans Progressiva (FOP) Treatment Market, by Drug Class (Corticosteroids, NSAIDs, Bisphosphonates, and Others), by Route of Administration (Oral, Topical, and Parenteral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022-2028

To Be Published : Nov 2024
Code : CMI3823
Formats :
Excel and PDF
Industry : Pharmaceutical

Fibrodysplasia Ossificans Progressiva (FOP) Treatment MarketSize and Trends

Global Fibrodysplasia Ossificans Progressiva (FOP) Treatment Market – Dynamics

Key players operating in market are increasing their research and development activities for the treatment for fibrodysplasia ossificans progressiva (FOP) which is expected to drive the growth of the global fibrodysplasia ossificans progressiva (FOP) treatment market during the forecast period. For instance, on November 2019, BioCryst Pharmaceuticals, Inc., a pharmaceutical company, initiated phase 1 clinical trial of BCX9250 which is an oral activin receptor-like kinase-2 (ALK-2) inhibitor, developed for the treatment of fibrodysplasia ossificans progressiva (FOP).

Moreover, market players are focusing on various inorganic strategies such as partnerships and agreement to develop the treatment for fibrodysplasia ossificans progressiva (FOP) which is expected to propel the marker growth during the forecast period. For instance, on October 2019, Clementia Pharmaceuticals, a subsidiary of Ipsen, and Blueprint Medicines Corporation entered an exclusive license agreement to commercialize and develop of BLU-782, a highly selective investigational ALK2 inhibitor, indicated for the treatment of fibrodysplasia ossificans progressiva (FOP).